Cancer drug eliminates aggressive cancers in Phase I trial

Published Date: 15 Aug 2025

Over the past 20 years, a class of cancer drugs called CD40 agonist antibodies have shown great promise—and induced great disappointment.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More Positive Survival Data in Lung Cancer With Perioperative Therapy

2.

Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy

3.

Study finds 10% of pediatric blood cancers may stem from medical imaging radiation

4.

For the creation of cutting-edge targeted radionuclide therapies in oncology, Bayer and Bicycle Therapeutics work together.

5.

Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot